COMMUNIQUÉS West-GlobeNewswire

Amoéba has received marketing authorization in France for its biofungicide AXPERA
01/07/2026
Chassieu, July 01, 2026 (GLOBE NEWSWIRE) -- Amoéba (FR0011051598 - ALMIB) , industrial greentech specialized in the development of natural microbiological solutions, announces that it has obtained marketing [...]
Amoéba obtient l’autorisation de mise sur le marché en France pour son biofongicide AXPERA
01/07/2026
Chassieu, 01 juill. 2026 (GLOBE NEWSWIRE) -- Amoéba (FR0011051598 - ALMIB) , greentech industrielle spécialisée dans le développement de solutions microbiologiques naturelles basées sur l’exploitation brevetée d’amibes [...]
Abivax announces trading resumption of its ordinary shares on Euronext Paris
01/07/2026
Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 02:50 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“ Abivax ” or the “ Company ”), a clinical- [...]
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
01/07/2026
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris PARIS, France, 1 er juillet 2026 – 14h35 CEST – Abivax SA (Euronext Paris : FR0012333284 – ABVX) (« Abivax » ou la « Société »), [...]
Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform
01/07/2026
Commercial Launch Begins Company's First Consumer Revenue Stream, Bringing Science-Backed Women's Health Solutions Directly to Consumers SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE [...]
Urteste S.A. Receives U.S. Patent for the Panuri Test
01/07/2026
Urteste S.A. Receives U.S. Patent for the Panuri Test Gdansk, Poland – 01 July 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine [...]
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
01/07/2026
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months Ramat Gan, Israel, [...]
Seer Prevails in European Patent Opposition as U.S. ITC Opens Investigation into Nanomics
01/07/2026
Seer's particle-based proteomics IP withstands challenges in both Europe and the United States REDWOOD CITY, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, [...]
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
01/07/2026
Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar NASHVILLE, Tenn., July 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management [...]
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
01/07/2026
Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program Ebstrocel for Epidermolysis Bullosa and Next-Generation Engineered Modalities Extending to 2045 BOCA RATON, Fla., [...]
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director
01/07/2026
Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contributed to multiple commercial therapeutics across haematology and oncology His appointment will strengthen Step Pharma’s [...]
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
01/07/2026
BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation [...]
Ocugen to Participate in Upcoming July Industry Conferences
01/07/2026
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/07/2026
CLEVELAND, July 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in [...]
FOXO TECHNOLOGIES INC. ANNOUNCES COMPLETION OF REVERSE STOCK SPLIT
01/07/2026
WEST PALM BEACH, FLORIDA, July 01, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (“FOXO” or the “ Company ”), today announced that its previously approved reverse stock split (the “Reverse Split”) of its [...]
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
01/07/2026
- Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% premium to Company’s [...]
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
01/07/2026
-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its [...]
Stryker to announce second quarter 2026 financial results
01/07/2026
Portage, Michigan, July 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, July 30, 2026 , to discuss its second quarter 2026 financial results. The live [...]
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
01/07/2026
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]

Pages